Informations générales (source: ClinicalTrials.gov)
Post-Covid Syndrome Cohort (SyPoCo)
Observational [Patient Registry]
Hospices Civils de Lyon (Voir sur ClinicalTrials)
avril 2023
avril 2029
29 juin 2024
SARS-CoV2 pneumonia has been a global public health emergency since 2020. The prevalence
of the disease is particularly high with more than 500 million cases worldwide (7.5
million in France) since the emergence of the virus.
A substantial proportion of patients with SARS-Cov2 infection present persistent symptoms
long after the acute infection. This is independent of the degree of severity of the
SARS-Cov2 infection.
These symptoms can affect the quality of life and impede the return to work. While the
majority of symptoms progress favourably with outpatient care, some persist and/or are
particularly severe, justifying expert and multidisciplinary care.
This investigation aim to create a clinical database of patients with complex and/or
severe post-CoviD and study blood markers what could predict the disease and orientate
new ways of treatment.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Department of Acute Pneumology and Thoracic Oncology, Hôpital Lyon Sud, Hospices Civils de Lyon - 69495 - Pierre-Bénite - France | Sébastien COURAUD, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
All patients who have joined the Epsilon care pathway since its opening in February 2022,
i.e.:
- Patients with post-Covid syndrome referred to the Epsilon sector from the city
medicine:
- Patient with documented SARS-Cov2 pneumonia
- With persistent and severe symptoms beyond 4 weeks or complex or disabling symptoms
beyond 3 months
- Patient over 18 years old.
Post-hospital sector:
- Patient with documented SARS-Cov2 pneumonia
- Hospitalized for oxygen therapy (at least 48h)
- Not having a referring pulmonologist
- Not institutionalized
- With a life expectancy of more than 6 months.
All patients who have joined the Epsilon care pathway since its opening in February 2022,
i.e.:
- Patients with post-Covid syndrome referred to the Epsilon sector from the city
medicine:
- Patient with documented SARS-Cov2 pneumonia
- With persistent and severe symptoms beyond 4 weeks or complex or disabling symptoms
beyond 3 months
- Patient over 18 years old.
Post-hospital sector:
- Patient with documented SARS-Cov2 pneumonia
- Hospitalized for oxygen therapy (at least 48h)
- Not having a referring pulmonologist
- Not institutionalized
- With a life expectancy of more than 6 months.
- Patient refusing that this data to be used for research purposes (objection form).
- Patient with untreated comorbidities